Should You Buy Minerva Neurosciences Inc (NERV) Stock on Wednesday?

Minerva Neurosciences Inc (NERV) stock has gained 3.79% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Minerva Neurosciences Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on NERV!

See Full NERV Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With NERV Stock Today?

Minerva Neurosciences Inc (NERV) stock is trading at $8.50 as of 9:48 AM on Wednesday, Sep 13, a rise of $0.40, or 4.94% from the previous closing price of $8.10. The stock has traded between $8.03 and $8.69 so far today. Volume today is less active than usual. So far 0 shares have traded compared to average volume of 32,848 shares. To see InvestorsObserver's Sentiment Score for Minerva Neurosciences Inc click here.

More About Minerva Neurosciences Inc

Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. The company primarily focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. Targeted disorders include schizophrenia, insomnia, major depressive disorder and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and major depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease. Click Here to get the full Stock Report for Minerva Neurosciences Inc stock.